Human study PLS-00144

Association between thymosin beta4 and non-alcoholic fatty liver disease.

Case-control study · Not reported participants enrolled · not included in the assessments (other)

Version 1 · published November 8, 2026 · evidence through November 8, 2026 · research snapshot 2026.1.1 · methodology ev-1 · Automated assessment by AI (claude-opus-5-5 and claude-sonnet-5-5), not reviewed by a person.

Only the abstract was available. Essential methods may be missing, which limits what can be judged.

Reports of this study

Every publication, registration and abstract describing this one study. Participants are counted once.

Association between thymosin beta4 and non-alcoholic fatty liver disease.primary · Revista espanola de enfermedades digestivas · 2019-04-01 · PMID 30896961 · DOI

Design and participants

Design: Case-control study
Population: Patients with non-alcoholic fatty liver disease and healthy controls
Conditions: Non-alcoholic fatty liver disease
Planned enrollment (registry): Not reported
Enrolled: Not reported
Randomized: Not reported
Completed follow-up: Not reported

Intervention and comparator

What each group received. Related peptides, analogs and combinations are never treated as the compound itself.

What the authors reported

As stated in the sources. This is the authors’ account, not Peptide Library’s assessment.

Adverse events

None reported. That is not evidence of safety, and how safety was monitored isn’t described.

The authors concluded (paraphrased): The authors concluded that serum Tβ4 may play a protective role in the development of NAFLD and that further studies are needed to confirm its role.

Peptide Library’s assessment

An automated assessment, made by AI separately from the authors’ conclusions and not reviewed by a person. How risk of bias is assessed.

Limitations

other: Tβ4 was measured as an endogenous serum biomarker and was never administered, so the study gives no information on its effects as a treatment.
abstract only: Only the PubMed abstract is available, and the multivariate result sentence is truncated in the record.
confounding: Observational case-control comparison; association cannot show causation, and the adjustment set is not fully described in the abstract.

No risk-of-bias assessment has been published for this study’s results.

Claims this study informs

Improves dry eye signs and symptoms: not eligible (not primary study) for “Ocular discomfort and corneal staining”
Is safe for human administration: not eligible (not primary study) for “Adverse events, serious adverse events and discontinuations”

Where each value comes from

author_conclusion: PMID 30896961, abstract (Conclusion) · extracted by AI (automated, not verified by a person) · abstract only
design: PMID 30896961, abstract (Patients and methods, sentences 1-2) · extracted by AI (automated, not verified by a person) · abstract only
population: PMID 30896961, abstract (Patients and methods, sentence 1) · extracted by AI (automated, not verified by a person) · abstract only

Version 1 · published November 8, 2026 · evidence through November 8, 2026 · research snapshot 2026.1.1 · methodology ev-1 · Automated assessment by AI (claude-opus-5-5 and claude-sonnet-5-5), not reviewed by a person.

These assessments describe published research. Records marked automated were produced by AI under the published methodology and have not been reviewed by a person; they can contain errors. None of this is medical advice, not a statement about any product’s safety for human use, and not a regulatory approval. Peptide Library’s vendor and partner relationships play no part in them (editorial independence).